Lyon Street Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Lyon Street Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-14,608	Closed	-$1.24M	–	48
2018 Q4	$1.24M	Sell	14,608 -255	-2%	-$27.2K	1.24%	33
2018 Q3	$2.54M	Sell	14,863 -36,414	-71%	-$5.49M	1.58%	17
2018 Q2	$6.63M	Sell	51,277 -14,659	-22%	-$1.64M	2.36%	12
2018 Q1	$6.79M	Buy	65,936 +2,207	+3%	+$218K	2.19%	14
2017 Q4	$5.44M	Buy	+63,729	New	+$5.52M	1.82%	21

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Lyon Street Capital's LGND Position: Q1 2019 in Review

Lyon Street Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 14,608 shares — an estimated $1.24M sold.

Lyon Street Capital first reported a position in LGND in Q4 2017 and held it in 5 quarters. The position peaked at $6.79M in Q1 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Lyon Street Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Lyon Street Capital sold 14,608 Ligand Pharmaceuticals shares in Q1 2019, an estimated $1.24M.
Lyon Street Capital first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Lyon Street Capital's Ligand Pharmaceuticals position peaked at $6.79M in Q1 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Lyon Street Capital's 13F filing for Q1 2019, filed 15 May 2019.